PDL, Roche settle drug-royalties fight; Swiss immigration limits would hit Roche, Novartis; 8th Circuit backs verdict against Novartis in Zometa case;

@FiercePharma: Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices. Story | Follow @FiercePharma

@TracyStaton: From FiercePharmaMarketing: UCB nabs Asian marketing rights to hot Biogen MS drugs. More | Follow @TracyStaton

@EricPFierce: My colleague Mark Hollmer offers a thoughtful analysis of pacemakers after having one put in. Check it out. Item | Follow @EricPFierce

@CarlyHFierce: More Humira sales gains help AbbVie meet forecasts. News | Follow @CarlyHFierce

> PDL Biopharma said it had settled its royalty disputes with Roche ($RHHBY), in a deal that grants it royalties on sales of the cancer drugs Avastin, Herceptin, Kadcyla, and Perjeta, as well as the asthma drug Xolair and eye drug Lucentis. Report

> A Swiss proposal to restrict immigration would interfere with drugmakers' ability to recruit skilled workers, Roche ($RHHBY) CEO Severin Schwan said, noting that half of the company's R&D staff are not Swiss, and nor is he. Report

> A U.S. appeals court affirmed a failure-to-warn verdict against Novartis ($NVS), even though the doctor who prescribed its drugs Zometa and Aredia said he didn't read the drug warnings. Report

> The Swedish drugmaker Recipharm tapped two local banks to advise on a potential stock market listing this year. Report

> Vertex Pharmaceuticals ($VRTX) cut the ribbon on its new Boston headquarters, which will house all of its area workers, including 1,200 already in place and another 100 moving in this quarter. Report

> Endo Health Solutions ($ENDP) wrapped up its sale of its HealthTronics unit to Altaris Capital for up to $130 million in cash and milestones. Report

Medical Device News

@FierceMedDev: FDA: Kids with diabetes can use DexCom's continuous glucose monitor. Story | Follow @FierceMedDev

@MarkHFierce: Here's my perspective, as a patient, on the pacemaker industry. Editor's corner | Follow @MarkHFierce

@MichaelGFierce: Lupin stakes a claim on the sterile injectables market. News | Follow @MichaelGFierce

@EmilyWFierce: Endo waves goodbye to HealthTronics for $130M. Report | Follow @EmilyWFierce

> Boston Scientific appears to turn a corner as sales growth gains momentum. More

> Thermo Fisher closes $13.6B Life Tech acquisition. Item

Biotech News

@FierceBiotech: Eisai readies applications for thyroid cancer drug after SFJ delivers PhIII success. More | Follow @FierceBiotech

@JohnCFierce: Furiex preps for buyout talks after IBS drug looks promising in PhIII. News | Follow @JohnCFierce

@DamianFierce: Big Pharma superteam joins NIH to share data, discover new drugs. Story | Follow @DamianFierce

@EmilyMFierce: Mechanism that boosts bone growth could aid osteoporosis drug design. Article via FierceBiotech Research | Follow @EmilyMFierce

> NEA backs $14M round for a biotech startup focused on autism disorder. More

> Acucela spots a $162M Japanese IPO to get its eye drug into focus. Read

Biotech Research News

> $40M gift from stem cell agency will fund new genomics initiative. Item

> Exposure to acid turns adult cells into stem cells. More

> Merck halts drug testing on chimpanzees. News

> Mechanism that boosts bone growth could aid osteoporosis drug design. Report

> Stem cell signaling protein spurs cancer spread. Story

> Epilepsy drug reverses fatty liver disease in obese mice. Article

Pharma Manufacturing News

> Daiichi Sankyo is bringing the hammer down on Ranbaxy. More

> Amgen is halting Epogen manufacturing in Colorado. Story

> Abbott is closing a plant in Puerto Rico as Mexico's Neolpharma expands. Article

> Alexion buys vial-filling facility in Ireland. News

> Lupin stakes a claim on the sterile injectables market. Report

> Sources: Recipharm looks at doing an IPO to expand cash. Item

And Finally... A sugary diet can double the risk of heart disease, a new study found. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.